CRSP - CRISPR Therapeutics AG

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
31.67
+0.49 (+1.57%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close31.18
Open31.15
Bid31.60 x 800
Ask31.83 x 900
Day's Range30.83 - 31.96
52 Week Range22.22 - 73.90
Volume628,076
Avg. Volume779,500
Market Cap1.64B
Beta (3Y Monthly)3.12
PE Ratio (TTM)N/A
EPS (TTM)-2.60
Earnings DateMar 6, 2019 - Mar 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est57.15
Trade prices are not sourced from all markets
  • Zacks15 hours ago

    Strong Friday Close Secures a 9th Week in the Green

    Strong Friday Close Secures a 9th Week in the Green

  • GlobeNewswire3 days ago

    CRISPR Therapeutics Proposes New Members to the Board of Directors

    CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect John T. Greene and Katherine A. High, M.D. to its Board of Directors at the Company’s upcoming annual general meeting to be held later this year. “We are very pleased to invite John and Kathy to join our Board of Directors. Together, they will bring significant strategic and operational experience to CRISPR Therapeutics during a critical stage of our company’s growth,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.

  • GlobeNewswire5 days ago

    CRISPR Therapeutics and StrideBio Expand Exclusive Development and Option Agreement

    ZUG, Switzerland and CAMBRIDGE, Mass. and Durham, N.C., Feb. 19, 2019 -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative.

  • Is Moderna a Buy?
    Motley Fool9 days ago

    Is Moderna a Buy?

    The biggest-ever biotech IPO heralds enormous promise for a new class of medicines.

  • Benzinga12 days ago

    Jim Cramer Gives His Opinion On Cronos, Etsy And More

    On CNBC's "Mad Money Lightning Round" , Jim Cramer said Cronos Group Inc (NASDAQ: CRON ) is at the top of the range. He would take some off the table on Tuesday. Manitowoc Company Inc (NYSE: ...

  • Here's Why CRISPR Therapeutics Rose 13.5% in January
    Motley Fool12 days ago

    Here's Why CRISPR Therapeutics Rose 13.5% in January

    The gene-editing pioneer announced a new regulatory designation for its lead drug candidate.

  • Should Sangamo's Failure Make CRISPR Investors Nervous?
    Motley Fool15 days ago

    Should Sangamo's Failure Make CRISPR Investors Nervous?

    The latest gene therapy to flop in a clinical trial pulled CRISPR stocks down with it.

  • Vertex Pharmaceuticals: New Drug, Same Great Growth Story
    Motley Fool16 days ago

    Vertex Pharmaceuticals: New Drug, Same Great Growth Story

    The biotech continues to make inroads in cystic fibrosis.

  • Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales
    Zacks18 days ago

    Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales

    Vertex's (VRTX) Q4 grows on earnings and revenue beat with rising demand for its CF products. Shares up.

  • Why Even a Pessimistic Analyst Thinks CRISPR Therapeutics Will Jump 20%
    Motley Fool19 days ago

    Why Even a Pessimistic Analyst Thinks CRISPR Therapeutics Will Jump 20%

    A huge downgrade for this gene-editing biotech still has a nice silver lining.

  • 3 Gene Therapy Stocks With Huge Catalysts in 2019
    Motley Fool20 days ago

    3 Gene Therapy Stocks With Huge Catalysts in 2019

    Clinical trial readouts on the way will move these stocks before 2019's finished.

  • 3 Biotech Stocks That Are Set for a Breakthrough
    InvestorPlace22 days ago

    3 Biotech Stocks That Are Set for a Breakthrough

    The future of medicine is all about the personalization of medicine. That means doctors will be able to tailor treatments that fit your specific ailments. Not the general ailments of a large population of people. Today, medicine is designed to treat the most common symptoms of a disease. So everyone with that same disease will be given the exact same treatment. But considering we all have different genetic makeups, this method is clearly not ideal. That is where gene editing -- the ability to edit a human's genome -- comes into play. InvestorPlace - Stock Market News, Stock Advice & Trading Tips The term "gene editing" oftentimes has a negative connotation. And given some of the post-apocalyptic movies that have become popular over the years, I can understand why some people are afraid. But genetic editing has so much to offer to the future of medicine. A couple of months ago, a Chinese scientist performed the first gene edit on a human by removing the gene that causes HIV in several newborns. The scientific community was not happy as most believe the science is not far enough along to verify its safety. However, the scientist proved that gene editing does have a place in the healthcare of tomorrow. There are currently more than 10,000 known monogenic diseases that do not have a cure. A monogenic disease is caused by the mutation of one gene. Yes, one single gene. Imagine being able to repair that gene and cure a disease immediately. That's exactly what science is working toward. Sickle cell disease is one of the terrible ailments that falls into this category. Today, those with this disease live with ongoing pain and the knowledge that their life will likely be shortened. But soon, science will be able to cure these people with a single procedure. * 10 Cold Weather Stocks to Heat Up Your Returns Imagine the diseases that could be irradiated through the practice of gene editing. There are many companies working toward this goal, and today I'd like to introduce you to three of the major biotech stocks to buy that focus on gene editing. Source: Shutterstock ### Crispr Therapeutics (CRSP) Crispr Therapeutics AG (NASDAQ:CRSP) is the largest of the Big Three gene-editing biotech stocks, and it has a slight lead in the race. The company made headlines in October when the Food and Drug Administration removed its clinical hold on CTX001, Crispr's gene therapy to treat sickle cell disease. Then, on Jan. 4, the FDA granted the therapy Fast Track status. This is extremely important because it allows for more frequent interaction with the FDA review team as well as a rolling review of the marketing application. Crispr Therapeutics is backed by some powerful pharma partners. Combine that with the promising treatments making headway in the United States and Europe and it is clear that this company is a great place to start investing in this innovative and inspiring trend that should make investors a lot of money. Source: Shutterstock ### Editas Medicine (EDIT) Editas Medicine (NASDAQ:EDIT) falls in the middle of the Big Three gene-editing biotech stocks to buy. It can trace its roots back to the biggest players in the industry, specifically Feng Zhang, whose affiliation with the Broad Institute has given Editas a significant leg up. The Broad Institute owns the patents to use Crispr technology in eukaryotic cells -- more complex cells that have a nucleus where the genetic material is found -- so it puts Editas in an enviable position since it has the exclusive rights to the patents for any genetic target it chooses. * 10 High-Yield Monthly Dividend Stocks This company's promising pipeline and connections make me confident that it is one of the key stocks to buy for investors interested in profiting from gene editing over the long term. Source: Pixelbay (Modified) ### Intellia (NTLA) Intellia Therapeutics (NASDAQ:NTLA) doesn't get the same amount of press as its fellow gene-editing stocks. It is also the smallest of the three, but its upside is just as huge as the other stocks to buy on this list. I say that because Intellia stands out thanks to its proprietary lipid nanoparticle delivery (LNP) technology. This takes drug therapies directly to the genes that need to be edited and does it right there rather than having to extract the gene edit it in the lab. The process has proven to be safer and more effective than the alternatives. Intellia has many irons in the fire as well as collaborations with two successful pharmaceutical companies, and I suspect it could have several therapies in FDA trials in the coming years. The key for gene-editing stocks to buy like NTLA will be to continue their partnerships and show progress, and that's exactly what it is doing. Source: Shutterstock ### Breakthrough Stocks I want to make one final note … gene-editing stocks are what I call buried treasure stocks … you could also call them breakthrough stocks since they're under the biotech frame. That means that the big returns I believe are possible take patience and time. Most investors don't have the long-term outlook that this kind of world-changing technology requires. * The 7 Best Penny Stocks to Buy If that's you, here is my suggestion: Go out and dig a big hole in your backyard. Bury these breakthrough stocks in it, and in 10 years you can dig up your buried treasure. Metaphorically speaking, of course. Matthew McCall is the founder and president of Penn Financial Group, an investment advisory firm, as well as the editor of Investment Opportunities and Early Stage Investor. He has dedicated his career to getting investors into the world's biggest, most revolutionary trends BEFORE anyone else. The power of being "first" gave Matt's readers the chance to bank +2,438% in Stamps.com (STMP), +1,523% in Ulta Beauty (ULTA), +1,044% in Tesla (TSLA), +611% in Liquefied Natural Gas Limited (LNGLY), +324% in Bitcoin Services (BTSC), just to name a few. If you're interested in making triple-digit gains from the world's biggest investment trends BEFORE anyone else, click here to learn more about Matt McCall and his investments strategy today. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 of the Best Stocks to Buy for a Dovish Federal Reserve * 5 Best Fidelity ETFs for Retirement Savers * 7 Blue-Chip Stocks That Could Lead the Market Higher Compare Brokers The post 3 Biotech Stocks That Are Set for a Breakthrough appeared first on InvestorPlace.

  • Is a Beat in Store for Vertex (VRTX) This Earnings Season?
    Zacks25 days ago

    Is a Beat in Store for Vertex (VRTX) This Earnings Season?

    On Vertex's (VRTX) fourth-quarter 2018 earnings call, investor focus will be on the sales figures of its newest CF drug, Symdeko.

  • CRISPR Stocks Flattened After 1 Downgraded Amid Steep Rivalry
    Investor's Business Daily26 days ago

    CRISPR Stocks Flattened After 1 Downgraded Amid Steep Rivalry

    Crispr Therapeutics stock tumbled Monday after an analyst downgraded it on a looming battle with Bluebird Bio in rare blood diseases. Crispr is using a gene-editing technique called CRISPR.

  • Benzinga27 days ago

    Goldman Sachs Steps To The Sidelines On Crispr Therapeutics

    Crispr Therapeutics AG (NASDAQ: CRSP ) has surged 24 percent since the start of the year, but one analyst sees little more room to run. The Rating Goldman Sachs analyst Salveen Richter downgraded Crispr ...

  • Vertex Terminates COO Ian Smith on Code of Conduct Violation
    Zackslast month

    Vertex Terminates COO Ian Smith on Code of Conduct Violation

    Vertex (VRTX) announces termination of its chief operating officer, Ian Smith, owing to violation of the company's code of conduct and values.

  • Better Buy: CRISPR Therapeutics vs. Editas Medicine
    Motley Foollast month

    Better Buy: CRISPR Therapeutics vs. Editas Medicine

    Which of these gene-editing stocks has the best chance to boost your portfolio?

  • Should You Sell CRISPR Therapeutics Following an Analyst Downgrade?
    Motley Foollast month

    Should You Sell CRISPR Therapeutics Following an Analyst Downgrade?

    Citigroup has downgraded the gene-editing pioneer to "sell," but Wall Street has been known to make mistakes.

  • Here's Why CRISPR Therapeutics Stock Fell Today
    Motley Foollast month

    Here's Why CRISPR Therapeutics Stock Fell Today

    A Wall Street analyst isn't too optimistic about the company's lead candidate.

  • GlobeNewswirelast month

    CRISPR Therapeutics and ProBioGen Sign Collaboration and License Agreement to Develop Novel In Vivo Delivery Technologies

    CRISPR Therapeutics (CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, and ProBioGen, a premier German service and technology provider, today announced a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise. “Our CRISPR/Cas9 platform has transformative potential across a broad range of devastating, genetically-defined diseases,” said Tony Ho, M.D., Executive Vice President, Research and Development at CRISPR Therapeutics.

  • Could CRISPR Therapeutics Be a Millionaire-Maker Stock?
    Motley Foollast month

    Could CRISPR Therapeutics Be a Millionaire-Maker Stock?

    This gene-editing biotech should have a huge growth opportunity in front of it. But is it enough to make you a millionaire?

  • 4 Gene-Editing Technologies That Could Replace CRISPR
    Motley Foollast month

    4 Gene-Editing Technologies That Could Replace CRISPR

    The future of medicine involves the precise engineering of human cells. Turns out, that future may not include that promising CRISPR technique.

  • Where Will CRISPR Therapeutics Be in 10 Years?
    Motley Foollast month

    Where Will CRISPR Therapeutics Be in 10 Years?

    This gene-editing biotech could boom or bust over the next decade. But one potential future seems much more likely.

  • Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence
    Investor's Business Dailylast month

    Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence

    Vertex Pharmaceuticals is the IBD Stock Of The Day as the leading biotech stock broke out in above-average volume The biotech is a leader in treatments for cystic fibrosis, a lung disease.

  • The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%
    Motley Foollast month

    The Best CRISPR Stock Gained 21% in 2018, While The Worst Lost 29%

    The three gene-editing pioneers had mixed results last year, but each has big plans for the year ahead.